2023-510374-13-00Not yet recruitingPhase 3
Intra-arterial t-PA infusion during mechanical thrombectomy in acute ischemic stroke: a randomized trial
Intra-arterial t-PA infusion during mechanical thrombectomy in acute ischemic stroke: a randomized trial.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 13 May 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The primary objective of this study is to determine whether the intra-arterial tPA infusion during mechanical thrombectomy (MT) might affect clinical and technical outcomes of patients with AIS due to LVO of the anterior circulation
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 15 Feb 2024
- Start date
- 31 May 2024
- Lead sponsor
- Vall D'hebron Institut De Recerca
- Diseases
- Stroke
- EU CT number
- 2023-510374-13-00
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 120
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a sudden stroke caused by a blocked large brain artery who are having a clot-removal procedure (thrombectomy). It tests giving the clot-dissolving drug t-PA directly into the artery during the procedure.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Stroke from a blocked large artery at the front of the brain (the internal carotid artery or the M1 part of the middle cerebral artery). Stroke symptoms with an NIHSS score of 6 or more. A dead-tissue (core) volume of 70 ml or less, with enough still-saved brain tissue on scans. Within 9 hours of stroke onset.
- Earlier treatment
- Before the stroke, daily life was fine or nearly so (mRS 1 or less). Patients sent from a secondary stroke center can join if the drip of t-PA into the vein ended 40 minutes before the control CT scan.
- Biomarker or test result
- The artery blockage must be confirmed by CT or MR angiography. Scan measures: core lesion 70 ml or less, and a mismatch ratio greater than 1.2 with a difference greater than 10 mL.
Main reasons for not taking part
- Any absolute reason not to get t-PA into a vein or artery
- Pregnant or breastfeeding women
- Known kidney disease
- Life expectancy under 90 days or advanced dementia
- Current or recent illicit drug use, or heavy alcohol use
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known renal disease
- Severe comorbid condition with life expectancy less than 90 days at baseline
- Known advanced dementia or significant pre-stroke disability (mRS≥2)
- Comorbid disease or condition that would confound the neurological and functional evaluations or compromise survival or ability to complete follow-up assessments
- Subject currently uses or has a recent history of illicit drug(s) or abuses alcohol (defined as regular or daily consumption of more than four alcoholic drinks per day).
Other
- Any absolute contraindication for IV or IA t-PA
- Radiological confirmed evidence of mass effect or intracranial tumor (except small meningioma)
- Radiological confirmed evidence of cerebral vasculitis
- CTA or MRA evidence of tandem occlusions of any cause
- Pregnancy or lactating women. A negative pregnancy test before randomization is required for all women with child-bearing potential.
- Known (serious) sensitivity to radiographic contrast agents, nickel, titanium metals, or their alloys
- Foreseeable difficulties in follow-up due to geographic reasons (e.g. patients living abroad)
Who the study is looking for
- Informed consent as documented by signature. It could be also an oral consent and subsequently signed.
- Patients admitted from a Secondary Stroke Center (SSC) eligible for EVT may be included in the VANISH protocol, if tPA infusion ended 40 minutes before a CT control, confirming the EVT indication
- Age ≥18
- Neurological deficit with a NIHSS of ≥6
- Pre-treatment mRs ≤1
- Patients eligible for endovascular treatment
- For IVT: Patient within 9 hours of stroke onset according to locally accepted guidelines. Patients with a wake up stroke, may be included if other inclusion criteria are satisfied. The ‘wake up’ stroke is defined as having no symptoms at sleep onset, but stroke symptoms on waking. The time of stroke onset is to be taken as the mid-point between sleep onset (or last known to be normal) and time of waking. The maximum time window for randomization is then 9 hours from the mid-point as described.
- Occlusion (TICI 0-1) of the intracranial internal carotid artery (ICA) and the M1 segments of the middle cerebral artery (MCA) confirmed by CT or MR angiography, accessible for MT
- An ischemic core lesion volume ≤ 70 ml using MR-DWI or CT-CBF
- A penumbral mismatch: a “hypo-perfusion to core” volume ratio of greater than 1.2 and an absolute difference greater than 10mL (using a MR or CT Tmax > 6 second delay) between perfusion lesion and MR-Diffusion Weighted Imaging (DWI) or CT- Cerebral Blood Flow (CBF) core lesion.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.